solute carrier family 38 member 1Genealiases: ATA1 · NAT2 · SAT1 · SNAT1
Q-omics provides the consensus-scored SLC38A1 profile across patient tissues and cancer cell-line models. SLC38A1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SLC38A1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SLC38A1 protein abundance shows 26,931 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KIRC, and LSCC as cancer lineages where SLC38A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC38A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC38A1 survival associations across molecular data types. SLC38A1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC38A1 RNA expression–survival associations across cancer types. High SLC38A1 expression shows unfavorable associations in LIHC, UCEC and LUAD, but favorable associations in SKCM, KIRC and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SLC38A1 RNA expression.
This table summarizes SLC38A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC38A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC38A1 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, KIRP, BLCA and LIHC. The KIRC box plot shows higher SLC38A1 RNA expression in tumor versus normal tissue (log2 FC = +1.191, t-test p < 0.001).
This table shows molecular features associated with SLC38A1 in patient tissues and cancer cell lines. In patient samples, SLC38A1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC38A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
